In summary, in a nondiabetic murine model of subtotal nephrectomy with low dose AngII‐driven hypertension, the initiation of the dual SGLT2/SGLT1 antagonist, sotagliflozin, one week after the last surgery, induced evidence for target engagement, including glucosuria, modest reduction in systolic blood pressure, temporal reduction in GFR, and an increase in GLP1 plasma levels, but did not improve signs of kidney injury, inflammation, fibrosis and albuminuria or signs of cardiac overload, fibrosis, or dysfunction. The gene discussed is SLC5A2; the disease is fibrosis.